title: Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease.
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, Florida 32610, USA.
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Dallas
authors.forename: Michael A
authors.initials: MA
authors.lastname: Jantz
authors.forename: Judith L
authors.initials: JL
authors.lastname: Lightsey
authors.forename: Christopher
authors.initials: C
authors.lastname: Sonntag
authors.forename: Frederic J
authors.initials: FJ
authors.lastname: Kaye
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000000981:diagnostic imaging; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D011859:Radiography; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride